Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms.

ELISPOT H1N1 antibody cross-reactivity attenuated PrV strain Bartha cross-protection heterologous prime-boost swine influenza A virus vaccination vectored vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
29 Oct 2022
Historique:
received: 29 09 2022
revised: 26 10 2022
accepted: 26 10 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 12 11 2022
Statut: epublish

Résumé

In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, we first vaccinated pigs intranasally with a pseudorabies vector vaccine expressing the pH1N1 hemagglutinin (prvCA09) followed by a homologous or heterologous WIV booster vaccine. Homologous and heterologous WIV-WIV vaccinated groups and mock-vaccinated or prvCA09 single-vaccinated pigs served as control groups. Five weeks after the second vaccination, pigs were challenged with a homologous pH1N1 or one of two heterologous H1N2 swine influenza A virus strains. A single prvCA09 vaccination resulted in complete protection against homologous challenge, and vector-WIV vaccinated groups were significantly better protected against heterologous challenge compared to the challenge control group or WIV-WIV vaccinated groups. Furthermore, vector-WIV vaccination resulted in broader hemagglutination inhibition antibody responses compared to WIV-WIV vaccination and higher numbers of antibody-secreting cells in peripheral blood, draining lymph nodes and nasal mucosa. However, even though vector-WIV vaccination induced stronger antibody responses and protection, we still failed to induce a pan-H1 antibody response.

Identifiants

pubmed: 36366335
pii: vaccines10111826
doi: 10.3390/vaccines10111826
pmc: PMC9699596
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : University of Ghent Research Fund Bijzonder Onderzoeks Fonds
ID : 01J102017

Références

Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578
pubmed: 28933664
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
Gene. 1987;57(2-3):261-5
pubmed: 2826296
Viruses. 2014 Aug 07;6(8):3055-79
pubmed: 25105278
Virus Genes. 2009 Oct;39(2):176-85
pubmed: 19597980
J Virol. 2012 Aug;86(16):8872-8
pubmed: 22696653
Microbiol Mol Biol Rev. 2005 Sep;69(3):462-500
pubmed: 16148307
Cell. 1982 Dec;31(2 Pt 1):417-27
pubmed: 6186384
J Gen Virol. 1997 Dec;78 ( Pt 12):3311-5
pubmed: 9400982
Vet Pathol. 1996 Mar;33(2):159-70
pubmed: 8801709
Bull World Health Organ. 1981;59(1):75-8
pubmed: 6973418
Nature. 2009 Jun 25;459(7250):1122-5
pubmed: 19516283
Front Immunol. 2021 Dec 14;12:808527
pubmed: 34970279
Clin Infect Dis. 2011 Jan 1;52(1):10-8
pubmed: 21148514
Viral Immunol. 2006 Summer;19(3):373-82
pubmed: 16987057
Infect Dis Poverty. 2022 May 13;11(1):53
pubmed: 35562753
Influenza Other Respir Viruses. 2011 Mar;5(2):67-75
pubmed: 21306569
J Virol. 2018 Apr 13;92(9):
pubmed: 29444938
Vet Rec. 2000 May 13;146(20):588-9
pubmed: 10839238
J Gen Virol. 2014 Apr;95(Pt 4):948-959
pubmed: 24431235
Vet Microbiol. 2000 May 22;74(1-2):117-31
pubmed: 10799784
J Gen Virol. 1998 Dec;79 ( Pt 12):2947-55
pubmed: 9880008
Pathogens. 2020 Oct 27;9(11):
pubmed: 33121171
Emerg Infect Dis. 2010 Feb;16(2):304-7
pubmed: 20113566
Can Vet J. 2009 Nov;50(11):1153-61
pubmed: 20119537
Vaccine. 2006 May 1;24(18):3881-8
pubmed: 16460844
Curr Top Microbiol Immunol. 2013;370:173-200
pubmed: 22976350
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):
pubmed: 35082157
mSphere. 2016 Dec 14;1(6):
pubmed: 27981236
Viruses. 2022 Jul 01;14(7):
pubmed: 35891443
Vet Pathol. 2012 Nov;49(6):900-12
pubmed: 22461226
NPJ Vaccines. 2017;2:
pubmed: 29250437
Protein Eng Des Sel. 2011 Mar;24(3):291-9
pubmed: 21123189
Viruses. 2020 Sep 01;12(9):
pubmed: 32882956
Immunol Rev. 2011 Jan;239(1):167-77
pubmed: 21198671
J Virol. 2012 Oct;86(19):10597-605
pubmed: 22811541
Clin Vaccine Immunol. 2012 Nov;19(11):1722-9
pubmed: 22933397
J Vet Diagn Invest. 2020 Mar;32(2):301-311
pubmed: 32100644
Vaccine. 2007 Jan 5;25(3):547-60
pubmed: 16920232

Auteurs

Anna Parys (A)

Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.

Elien Vandoorn (E)

Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.

Koen Chiers (K)

Laboratory of Veterinary Pathology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.

Katharina Passvogel (K)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany.

Walter Fuchs (W)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany.

Thomas C Mettenleiter (TC)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany.

Kristien Van Reeth (K)

Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.

Classifications MeSH